Will mutant strains hurt prospects for Roche's flu-fighting newcomer Xofluza?

Xofluza
Roche's Xofluza won FDA approval in late October. (Roche)

Xofluza, Roche’s bid to replace sales from the now-generic Tamiflu, has yet to catch on in the U.S., and new reports of viral resistance in Japan won’t help the drug’s case.

Some doctors in the country have slowed Xofluza prescribing in light of new evidence that mutant viral flu strains can stop the drug from working as intended in some patients, The Wall Street Journal reported. Tokyo’s National Institute of Infectious Diseases had ID’d six resistant strains as of Feb. 6.

As the institute noted, resistance issues cropped up in clinical trials for developer Shionogi; nearly 25% of children in late-stage trials had resistant strains, meaning the problem isn’t a new one.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

But it doesn’t bode well for Roche, which is looking to drive Xofluza growth in the face of copycats to predecessor Tamiflu. The new drug, which runs $150 for patients without insurance, has so far seen limited uptake thanks in part to its price; it generated just $13 million in the fourth quarter after snagging its FDA OK in October.

“Xofluza is very expensive and was just approved, so not many people are taking it,” Susan Wilder, M.D., an Arizona-based family doctor, told the WSJ.

RELATED: Roche’s next-gen flu drug works—but well enough to vie with Tamiflu generics?

Of course, Tamiflu is not without its own resistance issues. Xofluza is “extremely promising, especially in treating strains of flu that are resistant to Tamiflu,” Wilder said, adding that “Xofluza has a wider range of efficacy than other available flu drugs.”

But some doctors worry Xofluza will lose its edge if it gets too much play this year.

“There is the possibility that Xofluza will not be effective in the next flu season if it is widely used now, as this will cause drug-resistant viruses to spread quickly,” Naoto Hosokawa, head of the infectious-disease department at Kameda Medical Center near Tokyo, told the WSJ.

Meanwhile, Roche, for its part, pointed out that Xofluza still has some utility in mutant strains. While they showed “reduced susceptibility” to Xofluza, the drug still had some effect on them—meaning they’re not resistant by U.S. authorities’ standards. Further study is needed to determine the scope of the problem and the transmissibility of the strains in question, and a global study of how Xofluza affects flu spread is beginning this year, the company told the Journal.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.